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There are many interests in finding new chemotherapeutic agents for cancer. The current 
work involved screening of linamarin as the therapeutic agent on different cancer cells, as 
no such study has been performed previously. Improved bioavailability and delivery of 
the linamarin to the targeted tumour cells can be engineered by proper selection of its 
carrier. There are many advantages of choosing biodegradable nanoparticles as a drug 
carrier. These include an improved bioavailability and efficacy of the drug. It also offers 
a controlled release mechanism in which the activity of the drug can be prolonged at the 
affected sites. Besides, the biodegradability character of the carrier means these particles 
are easily dissolved in the system without exerting any side effects to the body. The 
present study investigated fabrication of linamarin encapsulation into biodegradable 
nanoparticles to kill cancer cells. 
The present study was initiated with an investigation of the toxic effect of linamarin on 
cancer cells and their cell cycles. The in vitro study on the effect of linamarin was 
performed on two tumour cell lines, HeLa (cervical tumour cell line) and CAOV3 
(ovarian tumour cell line). The cytotoxicity of linamarin was determined by the MTT 
assay. Both cell lines showed significant cell death when exposed to linamarin with the 
IC50 values well within the efficacious limit (IC50 of 30 mglml and 58 mglml for HeLa 
and CAOV3 cell lines, respectively, when exposed to pure linamarin). This result 
indicated that linamarin has the potential as a for drug candidate for cancer treatment. 
The subsequent cell cycle analysis performed by flow cytometry to determine the arrested 
point of linamarin within the cell cycle. Results showed significant effect of linamarin on 
the G1 phase of the cell cycle. In other words, a significant number of cells were being 
arrested in the G1 phase. However, no significant effect was observed on the S and G2-M 
stage of the cell cycle stage after treatment with the linamarin for 24 hours. 
The second part of the study was on fabrication of biodegradable linamarin loaded 
nanoparticles. Poly (lactic-co-glycolic acid) (PLGA) was chosen as the polymeric 
material of the nanoparticles. The water-in-oil-in-water emulsification process was the 
method of choice for the encapsulation of linamarin inside polymeric particles. The 
linamarin nanoparticles based on two different mole fraction of PLGA copolymer (50150 
and 85150 of lactic acidglycolic acid, respectively) were successfully fabricated using 
water-in- oil-in-water double emulsion extractionlevaporation technique. The SEM 
analysis on the morphologies of the nanoparticles showed the particles are spherical in 
shape with porous surface structure and well within nano-scale in size. 
A preliminary investigation on in vitro drug (linamarin) release was also carried out. The 
in vitro drug (linamarin) release was characterised by an initial burst and incomplete 
dissolution of the drug. When decreasing the polymer/drug ratio, the release appeared 
more controlled and prolonged up to 8hr. It can be concluded that nanoparticles prepared 
by water-in-oil-in-water emulsification followed by solvent evaporation is a good 
potential for a controlled released-drug carriers for linamarin. 
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Terdapat banyak minat dalam penemuan agen kemoterapi yang baru untuk penyakit 
kanser. Kajian ini melibatkan penyaringan linamarin sebagai agen terapi untuk pelbagai 
sel-sel kanser memandangkan tiada kajian yang sama dijalankan terdahulu. Peningkatan 
bioavailabiliti dan penghantaran linamarin ke sel-sel tumor yang ingin ditujui boleh 
dijuruterakan dengan pemilihan pembawa yang sesuai. Terdapat banyak kebaikan dalam 
memilih nanopartikel yang boleh dibiodegradasikan sebagai pembawa ubat. Ini termasuk 
peningkatan bioavailabiliti dan keberkesanan ubat. Ia juga membolehkan pengawalan 
terhadap mekanisma pelepasan di mana aktiviti ubat tersebut boleh diperpanjangkan di 
kawasan yang terjangkit. Disamping itu, sifat pembawa yang boleh dibiodegradasikan 
juga bermakna partikel-partikel tersebut mudah larut dalam sistem tanpa membawa 
sebarang kesan sampingan kepada badan. Kajian ini bertujuan mengaji fabrikasi 
linamarin yang dikapsulkan dalam nanopartikel yang boleh dibiodegradasikan untuk 
tujuan pembunuhan sel-sel kanser. 
Kajian ini dimulakan dengan menyiasat kesan ketoksikan linamarin terhadap sel-sel 
kanser serta kitaran selnya. Pengajian kesan linamarin di luar tubuh badan dilakukan ke 
atas dua jujukan sel tumor, iaitu HeLa (jujukan sel tumor servik) dan CAOV3 (jujukan 
sel tumor ovari). Sitotoksiksiti linamarin ditentukan dengan asei MTT. Kedua-dua jenis 
jujukan sel menunjukkan kematian sel yang nyata apabila didedahkan kepada linamarin 
pada nilai ICS0 yang berada di dalam julat keberkesanan. ( Nilai IC50 untuk HeLa adalah 
30 mglml dan 58 mglml untuk sel CAOV3 apabila kedua-dua sel ini didedahkan kepada 
linamarin yang tulen. Keputusan ini menunjukkan bahawa linamarin mempunyai potensi 
sebagai calon ubat dalam rawatan kanser. Kitaran sel yang kemudiannya dianalisasikan 
dengan flow sitometri menunjukkan kesan linamarin yang nyata pada fasa G1 kitaran sel. 
Ini bermakna terdapatnya nombor sel yang nyata yang telah disekat pada fasa GI. 
Walaubagaimanapun, tiada kesan yang nyata yang diperhatikan pada fasa S dan G2-M 
kitaran sel selepas dirawatkan dengan linamarin selama 24 jam. 
Bahagian kedua kajian ini adalah mengenai fabrikasi nanopartikel dengan muatan 
linamarin yang boleh dibiodegradasikan. Poli (laktik - ko - asid glikolik) (PLGA) dipilih 
sebagai bahan polimerik nanopartikel. Air-dalam-minyak-dalam air adalah proses 
pengemulsian yang dipilih untuk mengkapsulkan linamarin ke dalam partikel polimerik. 
Nanopartikel linamarin yang berasaskan dua pecahan mol kopolimer PGLA yang 
berlainan (50150 dan 85/15 masing-masing untuk pecahan mol asid laktik kepada asid 
glikolik) telah berjaya dihasilkan dengan teknik pengekstrakd penyejatan dua kali 
ganda pengemulsian air-dalam-minyak-dalam-air. Analisis morfologi nanopartikel 
vii 
dengan SEM menunjukkan bahawa partikel-partikel yang dihasilkan adalah dalam bentuk 
sfera dengan struktur permukaan yang berliang dan saiz yang berada dalam skala nano. 
Kajian pada peringkat awal tentang pelepasan ubat (linamarin) di luar tubuh badan juga 
dijalankan. Pelepasan ubat (linamarin) di luar tubuh badan bercirikan peletusan pada 
permulaan dan keterlarutan ubat yang tidak lengkap. Apabila nisbah polimer kepada ubat 
dikurangkan, pelepasan ubat didapati lebih terkawal dan berlanjutan sehingga 8 jam. 
Kesimpulannya, nanopartikel yang disediakan dengan pengemulsian air-dalam-minyak- 
dalarn-air dan diikuti dengan penyejatan pelarut merupakan satu potensi yang baik untuk 
pelepasan pembawa ubat linamarin yang terkawal. 
... 
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CHAPTER 1 
INTRODUCTION 
1.1 Introduction 
The drug delivery system is a system which delivers or carries the drug to the infected 
sites. The system is characterised by its ability to incorporate drugs without damaging 
them, long in vivo stability, its tuneable release kinetics and targeting to specific organs 
and tissues. This tuneable release kinetics is a characteristic for a controlled drug 
delivery mechanism. The controlled drug delivery offers many advantages over 
conventional dosage forms, including improved efficacy, reduced toxicity, improved 
patient compliance, and cost effective therapeutic treatment. In particular, the controlled 
release mechanism is strongly required for unconventional drugs, such as proteins and 
oligopeptides. 
In recent years, there has been significant effort to develop nanotechnology for drug 
delivery since it offers a suitable means for delivering small molecular weight drugs, as 
well as macromolecules such as protein, peptide or genes. Most of the works focus on 
formulation of therapeutic agents in biocompatible nano-composites such as 
nanoparticles, nanocapsules, micellar system, and conjugates. These systems are often 
polymeric based matrix and submicron in size. 
These nanotechnology systems can be used to provide targeted delivery of drugs, to 
improve the oral bioavailability and to sustain drug effect in cancer tissues. They can 
also be used to solubilize drugs for intravascular delivery and to improve the stability of 
therapeutic agents against enzymatic degradation. Much work in the past found that 
nanoparticulates drug carrier made of polymer appear to be more stable when in contact 
with biological fluids than other colloidal drug carriers (Kreuter et al., 1988; Zambaux 
et al., 1998). They also have been proposed as drug delivery systems for different routes 
of administration and for different types of active ingredients such as anticancer agents 
(Feng et al., 2003and Fonseca et al., 2002), anti-inflammatory compounds (Chacon et 
al., 1999), oligonucleotides (Lambert et al., 2001; Ulbrich et al., 2004) and peptides 
(Lemoine and Preat, 1998). 
Polymers can be used as a base matrix for nanoparticles. Polymeric nanoparticles 
generally vary in size from 10 to1 000 nm. The fabrication of polymeric nanoparticles is 
via dissolvement, entrapment, encapsulation or attachment of the drug to a polymer 
matrix. The polymers used to make the nanoparticles for administration into the human 
body are significantly limited to a few types of polymers due to their biocompatibility 
and biodegradation although various polymers can be employed to make nanoparticles. 
There has been intensive research in the development of nanoparticles of biodegradable 
polymers as an effective drug delivery system for medical practice, especially for 
chemotherapy and gene delivery. Progress in nanoparticles technology, material science 
of biodegradable polymers and cellular and molecular physiology and pathology have 
contributed to the advancements in chemotherapy and gene therapy of cancer and other 
disease with polymeric nanoparticles been considered as promising carriers for the 
therapeutic agent. 
Nanoparticulate delivery systems, based on poly (lactic-co-glycolic acid) (PLGA) 
polymers have been studied extensively for many years (Song.C.X, 1997). PLGA 
(lactic-co-glycolic acid) and its homo- or copolymers are the most widely used 
biodegradable polymers for fabricating nanoparticles. PLGA polymers have the 
advantage of being well characterized and have been commercially used as a 
microparticulate drug delivery systems. They are biocompatible, biodegradable and bio- 
resorbable. 
1.2. Problem Statement 
Chemotherapy is a complicated procedure in which many factors are involved in 
determining its success or failure. It carries a high risk due to drug toxicity and usually 
the more effective drugs tend to be more toxic. Problems related to drug side effects still 
exist even for success~l  chemotherapy, with patients not only have to tolerate the 
severe side effects but also sacrifice their quality of life. The effectiveness of 
chemotherapy depends on many factors, including the drug (s) used, the condition of 
the patient, the dosage and its form and schedule and others. 
Most anticancer drugs are highly hydrophobic, and hence are not soluble in water and 
most pharmaceutical solvents. Adjuvants have to be used for the clinical administration 
of many anticancer drugs and this may cause serious side effects, some of which are life 
threatening. Development of effective carriers with little side effects for anticancer 
